HSP90AA1 and non-small cell lung carcinoma: NCT-50 displayed weak but comparable cytotoxic effects in NSCLC cells compared with known Hsp90 inhibitors that have been evaluated in clinical trials such as ganetespib and PU-H7131,32 (Fig. 2d).